secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001493152-24-007143
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera cuts Ameluz transfer price to 25%, raises up to $16M in private placement
--------------------------------------------------------------------------------

- Transfer price reduced from 50% to 25% for 2024-2025; stepwise increases to max 35% from 2032; minimum dollar amount per unit.
- Company to assume control of all US clinical trials for Ameluz by June 1, 2024, improving cost management and oversight.
- Private placement led by Rosalind Advisors: $8M from Series B-1 Preferred, plus $8M warrants tied to milestones; up to $16M gross.
- Conversion price set at $0.7074 per share; Series B-3 conversion requires shareholder approval to increase authorized shares.
- Net proceeds to fund general operations and accelerate development of additional Ameluz indications (BCC, SCC, acne).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/0001493152-24-007143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315224007143/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer